More Options, More Hope
- New FDA approvals are giving people with breast cancer more treatment options, including camizestrant (Etcamah) for certain patients with hormone receptor-positive, HER2-negative advanced breast cancer whose cancer develops an ESR1 mutation.
- In the SERENA-6 trial, switching to camizestrant when blood tests detected an ESR1 mutation helped keep cancer from growing for longer than staying on standard hormone therapy.
- Dziarmaga says quality of life is as important as effectiveness, and she encourages patients to speak up and talk with their doctors about what’s best for them.
“It has been a remarkable year for AstraZeneca with respect to breast cancer launches and innovative therapies,” Dziarmaga says, highlighting five recent approvals that have expanded treatment possibilities.
Read MoreNew Treatment Options for Breast Cancer
Among the recent approvals is camizestrant (Etcamah), which received FDA accelerated approval in September for certain patients with hormone receptor-positive, HER2-negative advanced breast cancer. Hormone receptor-positive means the cancer uses hormones like estrogen to grow; HER2-negative means it doesn’t have high levels of a protein called HER2. It is the most common type of breast cancer. Accelerated approval lets the FDA make promising drugs available sooner while it collects additional data. Many of these patients are treated with an aromatase inhibitor, a hormone therapy that lowers estrogen, along with a CDK4/6 inhibitor, a targeted drug that slows cancer cell growth. Over time, some cancers develop a change, or mutation, in the ESR1 gene, which makes the estrogen receptor the cancer relies on. This change allows the cancer to keep growing despite hormone therapy.The SERENA-6 clinical trial used regular blood tests (sometimes called liquid biopsies) to catch these ESR1 mutations before scans showed the cancer was growing. Patients who switched to camizestrant while continuing their CDK4/6 inhibitor experienced longer progression-free survival, meaning their cancer was kept from growing for longer: a median of 16 months, compared with about nine months for those who stayed on their aromatase inhibitor.
But beyond the science, Dziarmaga says listening to patients remains essential to improving cancer care.
“For me personally, this is a very humbling experience,” she says. “What is really meaningful to me is when I interact with patients. They teach me a lot about what we should be looking for and what is meaningful to them.”
Balancing Treatment Advances With Quality of Life
While new medicines can help delay cancer progression, Dziarmaga emphasizes that treatment decisions must also consider how patients feel during therapy, especially for people with advanced breast cancer, who may stay on treatment for months or years.
“Quality of life is really important to these patients,” she says.
The goal, she explains, is to develop treatments that improve effectiveness while maintaining a tolerable safety profile. Every medicine carries potential side effects, making patient education and early recognition of complications important parts of care.
Dziarmaga also stresses the need to reach patients regardless of where they live, including through clinical trial access, education for health care professionals and patient support programs.
Above all, she encourages people facing breast cancer to participate actively in conversations about their treatment.
“Patients should be encouraged by the number of treatment options that are available to them today,” she says. “I would encourage them to have a voice and be proactive and have the courage to have the discussions with their health care providers on what is best for their cancer.”
Questions to Ask Your Doctor
- Is my breast cancer hormone receptor-positive and HER2-negative?
- Should I have regular blood tests to check for an ESR1 mutation?
- If my cancer changes, what treatment options are available to me?
- What side effects should I watch for, and how can they be managed?
- Are there clinical trials that might be right for me?
Learn more about SurvivorNet's rigorous medical review process.
